Actelion's share price rises after hedge fund calls on board members to go
This article was originally published in Scrip
Actelion saw its share rise on the Zurich market on 4 February following the revelation that Elliot Associates, a $17 billion hedge fund, had written to the Swiss biotech's board of directors demanding that certain board members step down. The letter claims that the individuals targeted are acting against shareholders' best interests in resisting a potential takeover. Actelion's share price rose by 3.6% to CHF54.40 after the letter was made public on 3 February.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.